You just read:

Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019

News provided by

Boston Biomedical, Inc.

Nov 08, 2019, 07:00 ET